Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin vs placebo in non-small cell lung cancer cachexia (ONO-7643-04)
jRCT2080222401Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) and cancer anorexia-cachexia syndrome (CACS) comparing Anamorelin with Placebo (2 arms). Primary endpoint: Lean body mass change. Started Feb 2014; status: completed.
02
Drugs
anamorelin
03
Conditions
non-small cell lung cancer (NSCLC)cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on jRCT2080222401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222401.